Navigation Links
CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Date:9/19/2007

KIRKLAND, Wash., Sept. 19 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has formed a new Device Division in order to develop, manufacture and market its patented line of stem cell cultivation and replication devices.

CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart.

Along with its planned human trials for its therapeutics, CellCyte Genetics intends to develop a new stem cell cultivation device or "bioreactor" unit for which CellCyte Genetics owns the worldwide patent and rights. The Company plans to market the device for applications that will require cells to be grown under regulated oxygen concentrations, e.g. the replication of stem cells and the culture of pancreatic islet cells prior to transplantation into diabetic patients.

Dr. Ron Berninger, Chief Scientific Officer of CellCyte Genetics explains, "CellCyte's patented biological cell maintenance system has the unique ability to incubate cultured cells with a very efficient and regulatable oxygen supply, making it an ideal choice for culturing cells that are otherwise difficult to keep alive or to expand. Inside the bioreactor, the cells can also form a 3-dimensional network, which is what most cell types do in major organs of the body."

A key element of this bioreactor is the capability to supply oxygen (by bundles of oxygen fibers) to the cells throughout the entire space in which cells are growing. Stem cells appear to be sensitive to oxygen levels and can be induced to replicate or differentiate in part by controlling the oxygen level.

Using CellCyte's product, scientists, researchers and clinicians should be able to dramatically increase the number of stem cells available for research and potentially for use in stem cell therapies. Management believes that the bioreactor unit will be the Company's first revenue producing research product and is expected be ready for market in 2008.

CellCyte Genetics acquired the patents and rights to the bioreactor unit and several other key technologies from the developer of the technology in 2006 as part of its original Intellectual property portfolio. The Company began work on remolding key parts of the bioreactor for manufacturing earlier this year as part of CellCyte's efforts to prepare for human trials and FDA application for the use of its stem cell therapies. With the manufacturing path and contract suppliers now set, CellCyte has begun gearing up this Device Division to complete development of the bioreactor and several other synergistic technologies.

The Device Division will operate as a separate division of the Company and will carry out R & D, manufacturing, and sales and marketing functions through the facilities of CellCyte Genetics' new facilities in Bothell near Seattle, Washington.

About CellCyte Genetics

CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products.

For further information see: http://www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Contact North America:

Investor Relations

Toll Free Telephone: 877.688.5050

Contact Europe:

Investor Relations

Telephone: (+49) 69.7593.8451

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.

THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.


'/>"/>
SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin court affirms damages in Innogenetics, Abbott patent case
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. Symposium examines the effect of race on genetics and disease
4. Metavante Corp. will continue M&A activity
5. Lucigen Corp. enters global licensing agreement
6. CIO Leadership Series: Jane Durment, Marcus Corp.
7. Brady Corp. acquires Korean counterpart
8. Brady Corp. raises $137 million in public offering
9. Symphony Corp. and CareEvolution to partner
10. RedPrairie Corp. introduces new supply chain software
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):